Bioventus Inc. (BVS): R&D Expense

Annual figures by period end, from SEC filings.

$12.11M
Year ended 2025-12-31
$11.57M
Trailing 12 months to 2026-06-27
-20.2%
3-year compound annual growth
+1.6%
5-year compound annual growth
$23.85M2019-12-31: $11.05M2020-12-31: $11.20M2021-12-31: $19.04M2022-12-31: $23.85M2023-12-31: $13.45M2024-12-31: $13.95M2025-12-31: $12.11M$12.11M
2019-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$12.11M-13.2%2026-03-05, From 2025-01-01
2024-12-31$13.95M+3.8%2026-03-05, From 2024-01-01
2023-12-31$13.45M-43.6%2026-03-05, From 2023-01-01
2022-12-31$23.85M+25.3%2025-03-11, From 2022-01-01
2021-12-31$19.04M+70.0%2024-03-12, From 2021-01-01
2020-12-31$11.20M+1.3%2023-03-31, From 2020-01-01
2019-12-31$11.05Mn/a2022-03-11, From 2019-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Bioventus Inc. (BVS)2025-12-31$12.11M-13.2%
UFP Technologies Inc (UFPT)2025-12-31$8.60M-17.3%
AtriCure, Inc. (ATRC)2025-12-31$99.21M+3.2%
Glaukos Corp (GKOS)2025-12-31$150.61M+10.4%
NovoCure Ltd (NVCR)2025-12-31$224.54M+7.1%
Artivion, Inc. (AORT)2025-12-31$30.99M+8.9%
iRhythm Holdings, Inc. (IRTC)2025-12-31$84.61M+18.4%
Alphatec Holdings, Inc. (ATEC)2025-12-31$76.27M-5.5%
Mimedx Group, Inc. (MDXG)2025-12-31$15.10M+22.3%

Compare BVS, UFPT, ATRC, GKOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗